OrbiMed’s SpringWorks Therapeutics SWTX Stock Holding History

OrbiMed’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-950,200	Closed	-$41.9M	–	118
2025 Q1	$41.9M	Sell	950,200 -304,831	-24%	-$14M	1%	29
2024 Q4	$45.3M	Sell	1,255,031 -135,600	-10%	-$4.74M	0.93%	31
2024 Q3	$44.6M	Sell	1,390,631 -316,700	-19%	-$11.8M	0.81%	38
2024 Q2	$64.3M	Hold	1,707,331	–	–	1.27%	22
2024 Q1	$84M	Sell	1,707,331 -1,512,028	-47%	-$69.9M	1.54%	21
2023 Q4	$118M	Sell	3,219,359 -749,229	-19%	-$19.6M	2.35%	10
2023 Q3	$91.8M	Sell	3,968,588 -210,000	-5%	-$5.74M	1.95%	12
2023 Q2	$110M	Sell	4,178,588 -320,312	-7%	-$8.42M	1.99%	13
2023 Q1	$116M	Sell	4,498,900 -751,100	-14%	-$22M	2.27%	12
2022 Q4	$137M	Sell	5,250,000 -275,926	-5%	-$6.8M	2.61%	8
2022 Q3	$158M	Sell	5,525,926 -502,381	-8%	-$14.4M	2.93%	4
2022 Q2	$148M	Hold	6,028,307	–	–	2.69%	7
2022 Q1	$340M	Hold	6,028,307	–	–	5.52%	1
2021 Q4	$374M	Hold	6,028,307	–	–	4.8%	1
2021 Q3	$382M	Sell	6,028,307 -15,959	-0.3%	-$1.23M	4.2%	1
2021 Q2	$498M	Sell	6,044,266 -142,041	-2%	-$10.8M	5.04%	1
2021 Q1	$455M	Sell	6,186,307 -1,220,000	-16%	-$95.5M	4.26%	1
2020 Q4	$537M	Hold	7,406,307	–	–	4.7%	2
2020 Q3	$353M	Hold	7,406,307	–	–	4.44%	2
2020 Q2	$311M	Hold	7,406,307	–	–	4.38%	1
2020 Q1	$200M	Hold	7,406,307	–	–	3.36%	4
2019 Q4	$285M	Hold	7,406,307	–	–	4.07%	4
2019 Q3	$161M	Buy	+7,406,307	New	+$175M	3.05%	8

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

OrbiMed's SWTX Position: Q2 2025 in Review

OrbiMed sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 950,200 shares — an estimated $41.9M sold.

OrbiMed first reported a position in SWTX in Q3 2019 and held it in 23 quarters. The position peaked at $537M in Q4 2020. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

OrbiMed reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 950,200 SpringWorks Therapeutics shares in Q2 2025, an estimated $41.9M.
OrbiMed first reported a position in SpringWorks Therapeutics in Q3 2019 and held it in 23 quarters.
OrbiMed's SpringWorks Therapeutics position peaked at $537M in Q4 2020.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.